

Subject Index

- Adjuvant treatment**, 69 (36)
 Chemotherapy – see Chemotherapy
 Early breast cancer, 74 (55), 123 (221)
 Endocrine therapy, 62 (14), 67 (30), 69 (38), 74 (53)
 Radiotherapy, 9 (E4), 72 (46), 134 (261), 162 (357)
- Anastrozole – see under Aromatase inhibitors**
- Angiogenesis**
 Prognostic factors, 91 (111)
 TGF-beta, 124 (226)
- Apoptosis – see Tumour biology**
- Arimidex – see Aromatase inhibitors, anastrozole**
- Aromatase inhibitors**, 164 (367)
 Adjuvant therapy, 71 (44), 140 (281)
 Anastrozole, 63 (18), 66 (28), 69 (37), 161 (354), 165 (369), 370, 167 (376), 200 (481)
 Early breast cancer, 71 (44), 161 (354)
 Exemestane, 62 (15), 75 (58), 165 (369), 167 (376), 200 (481)
 Letrozole, 66 (28), 69 (37), 90 (110), 160 (353), 167 (376), 200 (481)
 Neoadjuvant therapy, 73 (52), 75 (58), 96 (129)
 Post-menopausal patients, 73 (52), 78 (66), 160 (353), 164 (365)
 Tamoxifen, 62 (15), 160 (353), 223 (563)
- Axillary lymph nodes**, 149 (312), 159 (349), 231 (589), 236 (608)
 Adjuvant therapy, 128 (240)
 Biopsy, 230 (588)
 Early breast cancer, 128 (241)
 Lymph node dissection, 80 (74), 83 (85), 134 (259, 260), 136 (267), 137 (271), 139 (277), 145 (300), 147 (307), 150 (317), 153 (326)
 Lymphoedema, 125 (230), 134 (260), 145 (300)
 Micrometastasis, 127 (235), 141 (284), 147 (305, 307), 149 (313), 150 (318)
 Prognostic factor, 96 (131), 101 (148), 102 (150), 141 (284), 230 (587)
 Radiotherapy, 128 (240)
 Scintigraphy, 157 (340)
 Ultrasonography, 151 (321), 152 (324), 157 (342), 158 (343), 230 (586), 235 (607)
- Biopsy and Biopsy techniques**
 Core needle, 175 (405), 176 (408), 223 (561), 229 (582)
 Fine needle aspiration, 223 (561), 224 (564), 230 (588)
 Non-palpable lesions, 228 (581), 237 (612)
- Ultrasound guided, 229 (584), 230 (588), 234 (600), 237 (613), 238 (616)
 VAC mammotone, 175 (405, 407), 229 (583), 233 (598), 234 (600), 237 (612, 613)
 Wire-guided, 228 (581)
- Bisphosphonates**, 123 (221)
 Ibandronate, 123 (222)
 Pamidronate, 123 (222), 200 (483)
 Zoledronate, 63 (19), 65 (24), 90 (110), 123 (222), 164 (365), 191 (454), 200 (483)
- Bone marrow metastasis**, 102 (152), 113 (192), 120 (209), 123 (221), 146 (303)
- Bone metastasis (see also Metastatic/advanced breast cancer)**, 221 (557)
 Bisphosphonates, 123 (221, 222), 191 (454), 200 (483)
 Bone turnover, 191 (454)
 Prognostic factors, 132 (253)
 Response markers, 191 (454)
- Brain metastasis**, 38 (E18), 72 (47), 87 (99), 199 (479), 200 (482), 201 (486), 202 (490), 203 (491), 204 (495)
- Breast conserving surgery**, 134 (258), 142 (290), 150 (316), 214 (530), 227 (575)
 Aesthetic outcome, 83 (86), 129 (242), 135 (263, 264), 137 (270), 140 (283), 141 (286), 145 (299), 234 (603)
 Breast reconstruction, 77 (65), 135 (264), 137 (270), 141 (286, 287), 145 (299)
 Chemoradiotherapy, 140 (283)
 Ductal carcinoma in situ, 135 (262)
 Early breast cancer, 127 (236), 131 (250)
 Elderly/geriatric patients, 136 (265)
 Endoscopic surgery, 140 (283)
 Intra-operative radiotherapy, 126 (234), 128 (239), 129 (242, 244), 133 (255)
 Ipsilateral/contralateral tumour incidence, 119 (206)
 Local recurrence, 29 (E14), 65 (25, 26), 91 (113), 92 (114), 96 (128), 119 (206), 121 (215), 122 (218), 128 (239, 241), 129 (244), 133 (256), 139 (280), 141 (285), 206 (501), 211 (519)
 Neo-adjuvant chemotherapy, 60 (9), 63 (17), 65 (25, 26), 138 (276)
 Non-palpable breast tumours, 143 (291), 146 (301)
 Radiotherapy, 128 (239, 241), 129 (242, 244), 131 (250)
 Residual tumour, 133 (256)
 Surgical practice, 44 (E21), 135 (263), 141 (286, 287), 146 (301), 206 (501)
 Ultrasound guided surgery, 146 (301)

*Page numbers are followed by the abstract numbers in parentheses.

Breast Units, 15 (E6), 27 (E13), 59 (1, 2), 133 (257), 183 (422), 211 (518), 213 (526), 230 (586)

c-erbB-2 – see Her-2/neu

Carcinoma intraductal, 122 (216, 217), 123 (219), 141 (284), 223 (562), 226 (574), 233 (597)

Chemotherapy/adjunct chemotherapy, 76 (59), 111 (181), 116 (203), 152 (324), 192 (457), 195 (467)
 Anthracyclines, 24 (E12), 72 (46, 48), 73 (49, 50), 120 (210), 121 (213), 184 (430), 193 (461), 202 (489)
 Antimetabolites, 94 (123), 193 (460), 195 (468), 196 (470), 471, 197 (472), 198 (475), 199 (477, 478), 201 (484, 485), 202 (487), 204 (496)
 Chemosensitivity prediction, 120 (210, 211), 121 (213), 124 (223), 137 (269)
 CMF, 73 (51)
 Dosage and schedules, 69 (39), 71 (43)
 Doxorubicin, 68 (35), 75 (57), 113 (191), 192 (456)
 Early breast cancer, 55 (7N), 59 (7), 71 (43), 163 (362)
 Epirubicin, 68 (34), 197 (473)
 FEC, 163 (363)
 5FU, 94 (123), 100 (144)
 High risk patients, 120 (209)
 Locally advanced breast cancer, 75 (56, 57), 192 (456), 193 (460, 461)
 Neoadjuvant chemotherapy, 20 (E10), 65 (24), 66 (27, 29), 68 (33, 34), 70 (42), 71 (45), 72 (48), 73 (50), 75 (56, 57), 94 (121, 123), 101 (147), 124 (223), 127 (238), 130 (247), 134 (259), 137 (269), 138 (276), 148 (311), 149 (313), 150 (317), 157 (341), 158 (345), 173 (399), 190 (451), 193 (460)
 Pre-/perimenopausal patients, 62 (14)
 Predictive factors, 71 (45), 100 (144), 101 (147)
 Taxanes, 17 (E7), 64 (23), 70 (40), 71 (43), 72 (48), 94 (123), 163 (362, 363), 166 (375), 190 (450), 193 (460), 195 (468), 216 (536)
 Toxicity and side effects, 24 (E12), 68 (35), 69 (39), 70 (40), 73 (49), 74 (53), 75 (57), 162 (359), 163 (362, 363), 164 (365, 366), 166 (372, 373), 184 (430), 196 (469), 205 (499), 247 (639)

Clinical practice/guidelines/attitudes

Breast cancer management, 2 (E1), 18 (E8), 27 (E13), 31 (E15), 59 (1, 2, 5), 76 (61), 78 (67), 96 (131), 125 (227), 133 (257), 142 (288), 174 (402), 183 (422, 423), 188 (444), 189 (446), 194 (465), 205 (498), 208 (507, 508), 211 (518), 212 (523, 524), 213 (525, 526), 216 (538), 217 (539), 218 (542, 544), 219 (549), 221 (555), 222 (558), 244 (638)
 Data management, 101 (146), 187 (441), 208 (508), 214 (531)
 Education, 77 (63, 65), 78 (68), 85 (92), 189 (448), 212 (524), 213 (526), 244 (638)
 Guidelines, 18 (E8), 76 (59), 122 (218), 127 (237), 185 (435), 187 (440, 441), 188 (444), 189 (447), 211 (518), 214 (530), 215 (534), 227 (575), 244 (638)
 Quality control, 27 (E13), 59 (1, 2, 5), 76 (59), 84 (90), 133 (257), 142 (288), 183 (423), 189 (446, 447, 448), 191 (453), 209 (512), 212 (523), 213 (528), 214 (531), 216 (538), 234 (603)

Clinical trials, 54 (5N, 6N), 55 (8N), 62 (15), 64 (22), 68 (34), 87 (101), 89 (106), 125 (230, 231), 129 (242), 131 (249), 142 (289), 168 (379), 188 (444), 190 (449, 450), 197 (472), 198 (476), 202 (489), 207 (505), 210 (515), 214 (530)

Computers/simulation, 227 (577), 232 (593), 233 (596, 597), 234 (603), 240 (626)

Costs and cost control, 63 (19), 66 (28), 208 (509), 214 (529), 215 (534), 217 (540), 218 (544), 241 (628), 242 (634), 244 (638)

Diagnosis, 168 (380), 236 (610), 237 (611)

Axillary lymph node involvement, 158 (343), 235 (605)
 Benign mammograms, 229 (585), 231 (591)
 Biopsy techniques, 151 (319), 153 (327, 328), 175 (405), 223 (561), 224 (564), 228 (581), 229 (582), 234 (600), 237 (612, 613, 614), 238 (616)
 Delayed diagnosis, 240 (624)
 Ductal carcinoma in situ, 177 (413)
 Familial cancer, 224 (565)
 Metastasis, 221 (557), 231 (592)
 Nipple discharge, 234 (602)
 Non-palpable lesions, 110 (179), 174 (400), 228 (579, 581)
 Non-screening setting – mammography & ultrasound, 11 (E5), 238 (615)
 Phylloides tumour, 222 (560)
 Recurrent disease, 231 (592)
 RT-PCR techniques, 110 (179), 154 (330), 155 (335), 170 (386, 387), 172 (395), 226 (571)
 Self-examination, 220 (550), 240 (624)
 Triple diagnostic approach, 229 (585), 237 (614)

Diagnostic imaging, 221 (557), 232 (595), 236 (608), 242 (632)

Lymphoscintigraphy, 155 (336), 157 (340)
 Mammography, 22 (E11), 78 (68), 175 (404), 186 (437), 223 (562), 224 (565), 227 (577), 231 (591), 232 (593), 233 (596, 597), 235 (606), 237 (611), 239 (621, 622), 240 (625, 626)
 MRI, 66 (27), 70 (42), 151 (321), 174 (401), 175 (406), 176 (409), 186 (437), 223 (562, 563), 224 (565), 227 (575), 228 (578, 580), 229 (583), 231 (590, 591), 232 (594), 236 (609), 238 (616, 617, 619), 240 (625)
 PET/CT, 72 (47), 159 (348), 225 (567, 568), 226 (572, 573, 574), 230 (587), 231 (589, 592), 235 (605), 239 (620), 243 (635)
 Scintimammography, 71 (45), 238 (615)
 Ultrasonography, 11 (E5), 22 (E11), 68 (33), 151 (321), 160 (352), 174 (400), 175 (404), 224 (565), 230 (586), 235 (604, 606, 607)

Docetaxel, 111 (181), 163 (362), 166 (372)

Adjuvant therapy, 71 (43), 73 (49), 163 (363), 184 (430), 216 (536)
 Doxorubicin, 70 (40)
 Metastatic/advanced disease, 55 (8N), 93 (120), 199 (480)
 Neoadjuvant therapy, 60 (8), 68 (34)
 Predictive/prognostic factors, 94 (123), 113 (189)

Drug resistance, 124 (223), 183 (425, 426)

Ductal carcinoma in situ, 148 (309), 163 (361)

Breast conserving surgery, 135 (262)
 Histopathology/classification, 108 (173), 149 (314), 168 (382), 170 (388), 177 (413), 186 (438)
 Local recurrence, 207 (506)
 Magnetic resonance imaging, 176 (409), 186 (437), 223 (562)
 Predictive factors, 100 (143), 187 (439)
 Prognostic factors, 100 (143), 187 (439)
 Radiological features, 186 (437)
 Screening, 176 (411)

- Early breast cancer**, 31 (E15), 72 (47), 109 (175), 123 (221), 153 (327, 328), 156 (339), 163 (362), 174 (400), 219 (549)
 Adjuvant chemotherapy, 64 (22), 71 (43), 73 (49), 163 (363), 216 (536)
 Adjuvant tamoxifen, 74 (53)
 Aromatase inhibitors, 71 (44)
 Breast conserving surgery, 127 (236), 128 (241), 131 (250), 133 (255)
 Herceptin, 59 (7), 73 (49, 50)
 Mastectomy, 138 (274)
 Neo-adjuvant chemotherapy, 60 (10, 8), 64 (23), 72 (48), 73 (50), 130 (247)
 Prognostic factors, 73 (51), 89 (106, 107), 96 (130), 100 (143), 101 (149), 104 (158), 112 (185), 146 (303), 212 (522)
 Radiofrequency ablation, 139 (278)
 Radiotherapy, 127 (236), 128 (241), 130 (247, 248), 131 (250, 252), 133 (255), 164 (364)
 Registry data, 89 (107), 96 (130), 242 (633)
 Second cancers, 89 (106)
- Elderly/geriatric patient care**, 46 (E22), 122 (216), 136 (265), 192 (458), 196 (471), 242 (631, 634)
- Endocrine therapy/adjuvant endocrine therapy**, 60 (9), 61 (13), 62 (14), 63 (18, 19), 64 (20), 67 (30, 31, 32), 69 (38), 73 (52), 74 (53, 54), 75 (58), 87 (101), 96 (129), 99 (139), 103 (156), 111 (182), 149 (313), 160 (353), 161 (354), 165 (368, 369, 370), 167 (377), 178 (415), 179 (419, 420), 192 (458), 193 (459), 204 (497), 223 (563)
- EORTC trials**, 54 (6N), 89 (106), 124 (223), 127 (237), 188 (444)
- Epidemiological studies**, 84 (88), 88 (103), 191 (453), 205 (499), 206 (500, 501, 502, 503), 207 (504, 505, 506), 208 (507, 508, 509), 209 (510, 511, 512, 513), 210 (514, 515, 516), 211 (517, 518, 519, 520), 212 (521, 522, 523, 524), 213 (525, 527, 528), 214 (529, 530), 215 (533), 216 (536, 537), 217 (541), 219 (546), 220 (550), 221 (556), 239 (623), 240 (627), 242 (631)
- Estrogen and progesterone receptors**, 60 (9), 74 (54), 91 (112), 99 (139), 103 (155), 105 (161), 106 (167), 109 (176), 110 (180), 112 (187), 113 (191), 168 (381), 170 (386, 387), 185 (435), 229 (582)
- Exemestane – see under Aromatase inhibitors**
- Familial cancer/genetic testing**, 210 (516), 212 (522)
 BRCA1/BRCA2 carriers, 55 (7N), 60 (10), 91 (113), 103 (154), 108 (172), 109 (177), 136 (268), 185 (431), 206 (500), 222 (559), 224 (565, 566), 240 (625)
 BRCA1/BRCA2 prevalence/screening, 109 (177), 213 (527)
 Genetic counselling, 220 (553), 241 (630)
 Ipsilateral/contralateral tumour incidence, 224 (566)
 Mammography, 224 (565), 239 (622)
 MRI imaging, 224 (565)
 Ovarian cancer, 224 (566)
 Patient/family communication, 241 (630)
 Prophylactic surgery, 136 (268)
 Risk estimation, 220 (553), 224 (566), 241 (630)
 Surveillance, 222 (559), 224 (565)
- Gene therapy**, 86 (95)
- Her-2/neu**, 72 (47), 110 (178), 114 (193), 175 (406)
 ER positive tumours, 20 (E10), 109 (176)
 FISH, 121 (213), 227 (576)
 Gene expression profiling, 112 (187), 178 (416)
 Herceptin, 74 (55)
 Immunohistochemistry, 229 (582)
 p53, 212 (522)
 Predictive/prognostic factor, 60 (10), 61 (12), 112 (184), 114 (195), 115 (198), 121 (213), 186 (436), 203 (493)
- Histology**, 86 (97), 93 (118), 94 (121), 95 (127), 100 (145), 103 (155), 108 (173), 121 (213, 214), 146 (303), 147 (306), 151 (320, 322), 152 (323), 154 (330, 331), 155 (335), 156 (337, 339), 157 (342), 159 (350), 168 (382), 171 (390), 172 (394, 395), 173 (397), 218 (543, 545), 226 (571, 573), 227 (576), 228 (579), 229 (582, 584), 232 (595), 233 (598)
- Immunology and immunotherapy**, 107 (171)
 Chemotherapy effects, 59 (7), 90 (108)
 Immunotherapy, 68 (35), 69 (36), 73 (49, 50), 74 (55), 87 (98), 90 (108), 94 (122), 123 (221, 222), 162 (357), 178 (418), 186 (436), 196 (469, 470), 198 (475, 476), 201 (486), 202 (489, 490), 203 (492), 204 (496), 217 (540)
 Vaccines, 87 (101)
- Invasive lobular cancer**, 121 (214, 215), 122 (216, 217, 218), 123 (219), 174 (401, 402), 176 (410), 177 (412), 233 (597)
- Letrozole – see under Aromatase inhibitors**
- Lymphoedema**, 125 (230), 134 (260), 145 (300), 161 (355), 162 (360), 165 (371), 219 (548)
- Male breast cancer**, 136 (266)
- Metastatic/advanced breast cancer**, 87 (99), 122 (216), 169 (383), 192 (455), 196 (471), 197 (472), 198 (475), 201 (485, 486), 202 (490), 203 (492), 204 (494, 496), 231 (589)
 Adjuvant chemotherapy, 120 (209)
 Aromatase inhibitors, 90 (110), 200 (481)
 Bisphosphonates, 200 (483)
 Bone (see also Bone metastasis), 132 (253), 200 (483)
 Clinical management, 19 (E9), 150 (317)
 Docetaxel, 93 (120), 196 (469), 199 (480)
 Endocrine therapy, 64 (20), 67 (30), 178 (415), 202 (487), 204 (497)
 Gemcitabine, 196 (470)
 Neo-adjuvant chemotherapy, 70 (42), 71 (45), 75 (56, 57), 127 (238), 138 (276), 158 (345)
 Paclitaxel, 193 (460), 195 (468), 196 (469, 470), 198 (476), 201 (484)
 Prognostic factors, 62 (16), 75 (56), 90 (108), 102 (152), 115 (198), 203 (491, 493), 204 (495), 205 (498)
 Vinorelbine, 192 (457), 197 (474)
- Nursing**, 76 (61), 84 (88, 89, 90), 85 (91, 92, 93), 207 (505)
- Paclitaxel**, 68 (35), 75 (57), 86 (96), 88 (104), 91 (111), 197 (473), 198 (476), 201 (484)
- Palliative care**, 217 (539)
- Pathology**, 93 (118, 119), 100 (145), 103 (155), 104 (159), 108 (173, 174), 116 (200), 121 (213, 214), 137 (269),

Pathology (*cont'd*)

141 (285), 146 (304), 147 (306), 149 (314), 150 (316),
151 (320, 322), 154 (331), 155 (335), 159 (350),
168 (380, 382), 169 (383, 384, 385), 170 (386, 387, 388,
389), 171 (390, 391, 392, 393), 172 (394, 395, 396),
173 (397, 399), 174 (402), 175 (405, 406), 176 (410),
177 (412, 413), 178 (416), 186 (438), 187 (439),
188 (443), 194 (465), 202 (488), 215 (532), 218 (543,
545), 221 (554), 223 (561), 226 (571, 573), 228 (579),
229 (582), 231 (590), 232 (595), 233 (598)
Inprint cytology, 152 (323), 156 (337), 157 (342)

Pharmacogenomics/Pharmacogenetics, 61 (13), 96 (129),
120 (210, 211), 121 (213), 124 (223), 179 (419, 420,
421), 192 (456), 214 (529)

Phylloides tumour, 222 (560)

Predictive and Risk factors, 61 (11), 79 (70), 95 (125),
98 (137, 138), 102 (152), 140 (282), 200 (482), 206 (503),
209 (510, 511), 210 (514), 211 (517, 520), 217 (541),
220 (550, 551, 553), 225 (569, 570), 226 (573)
Bcl-2, 88 (104)
Bone turnover markers, 164 (365)
BRCA1/p130Cas gene, 91 (113), 103 (154), 185 (431),
206 (500), 213 (527)
Estrogen receptor, 91 (112), 95 (124), 99 (139, 141),
101 (147), 103 (155)
Gene expression profiling, 88 (102), 95 (127), 107 (170),
124 (223), 161 (356), 226 (571)
Genetic markers – genomic comparison, 88 (102), 93 (118),
102 (151), 120 (210, 211), 124 (223), 161 (356), 214 (529)
Her-2/neu, 48 (E23), 61 (12), 85 (94), 92 (115), 93 (120),
96 (130), 97 (133), 99 (141), 103 (156), 105 (162),
112 (184)
New markers, 62 (16), 95 (126), 100 (142), 104 (158),
114 (194)
p53, 89 (105), 104 (157), 212 (522)
PET, 230 (587)
Residual tumour, 133 (256)
Response to therapy, 60 (8), 71 (45), 75 (56), 114 (195),
120 (210, 211), 121 (213), 122 (216), 124 (223), 137 (269),
169 (384), 188 (443), 214 (529), 228 (578)
Scintimammography, 71 (45), 204 (497)
Sentinel lymph node, 127 (235), 147 (305), 150 (317),
152 (325), 155 (334)
VEGF, 94 (122)

Pregnancy and Fertility, 77 (64), 166 (375), 205 (499),
206 (502), 207 (504), 216 (537)

Prevention, 220 (553)

Endocrine therapy, 212 (521)
Lifestyle factors, 76 (60), 119 (204), 220 (550)
Prophylactic surgery, 206 (500), 222 (559)
Public attitudes, 76 (60), 220 (550)

Prognostic factors, 60 (8), 61 (11), 67 (31), 70 (41), 79 (70),
90 (109, 110), 92 (114), 98 (136, 138), 99 (140),
101 (149), 105 (163), 106 (165, 166), 113 (192),
146 (304), 150 (315), 156 (338), 160 (351), 192 (456),
200 (482), 206 (502, 503), 207 (504), 210 (514),
225 (570), 226 (571), 234 (601)
Axillary lymph node status, 96 (131), 101 (148), 102 (150),
141 (284), 146 (303), 171 (393), 230 (587)
Blood- and lymphatic vessel invasion, 95 (125), 170 (389)
CA 15-3, 104 (159)

Contralateral/ipsilateral tumours, 55 (7N), 89 (106), 95 (124),
228 (580)
Estrogen receptor, 91 (112), 95 (124), 99 (139, 141),
101 (147), 103 (155), 105 (160), 132 (253), 185 (435),
199 (479)
Extracapsular extension, 115 (199), 116 (200)
Her-2/neu, 48 (E23), 61 (12), 66 (29), 92 (115), 93 (117,
120), 96 (130), 97 (133), 99 (141), 103 (156), 105 (160,
162), 106 (167), 107 (171), 112 (184), 132 (253), 185 (435)
Invasive lobular cancer, 94 (121), 98 (137), 174 (401, 402),
176 (410), 177 (412), 187 (440), 199 (479)
Mitotic index, 100 (145), 104 (159)
Multicentric breast cancer, 101 (146)
New markers, 48 (E23), 62 (16), 89 (105), 95 (126), 98 (137),
100 (142, 144), 102 (151), 106 (164), 107 (168), 111 (183),
114 (194, 196), 115 (197), 116 (202, 203), 173 (398)
p53, 97 (134), 98 (135), 104 (157), 212 (522)
Tumour size, 88 (103), 97 (132), 103 (153)
Urokinase-type plasminogen activator/inhibitor (uPA/PAI-1),
89 (107)
VCAM-1, 94 (122)
VEGF, 87 (100)
Young age (<35 yrs), 219 (547), 221 (556)

Psycho-oncology, 247 (639)

Breast reconstruction, 77 (65), 81 (77), 82 (81), 138 (274),
184 (427)
Counselling, 76 (61), 81 (79), 83 (84), 125 (228), 148 (308),
210 (515)
Education, 76 (62), 77 (63), 78 (66, 69), 80 (74, 75), 82 (81),
125 (228), 207 (505), 209 (513), 221 (555)
Family life, 33 (E16), 78 (69), 80 (75), 82 (82)
Follow-up, 208 (507), 213 (525), 219 (549), 221 (555)
Patient/family communications, 40 (E19), 77 (63), 80 (75),
126 (234)
Patient survey, 77 (63)
Psychological morbidity, 77 (64), 79 (71, 72, 73), 80 (76),
81 (77, 78, 79), 82 (82, 83), 83 (84, 85, 87), 85 (93),
125 (227), 162 (359), 207 (505), 210 (515)
Psychosocial support, 77 (65), 80 (76), 84 (89), 85 (93),
125 (227)
Public awareness, 189 (448), 215 (533), 220 (550)
Quality of life, 33 (E16), 73 (52), 79 (71, 72, 73), 80 (74),
82 (80), 83 (85, 86), 125 (228), 127 (236), 137 (272),
142 (289), 165 (371), 167 (378), 184 (430), 190 (449),
197 (473), 207 (505), 209 (513), 214 (530)
Rehabilitation, 76 (61), 80 (74), 125 (228), 162 (358)
Risk explanation, 126 (233)

Radiotherapy/adjunct radiotherapy, 121 (215), 125 (231),
128 (240), 134 (261), 168 (379), 184 (428), 195 (466)

Brachytherapy, 130 (245), 144 (295)
Breast conserving therapy, 35 (E17), 91 (113), 126 (234),
127 (236), 128 (239), 129 (242, 244), 131 (252), 133 (255),
144 (295)
Chemoradiotherapy, 72 (46)
3D-planning, 130 (246)
Dose delivery, 129 (243), 131 (251), 132 (254)
Early breast cancer, 130 (247), 131 (250), 164 (364)
IMRT, 35 (E17)
Internal mammary lymph nodes, 54 (5N, 6N), 162 (357)
Intra-operative radiotherapy, 126 (234), 128 (239), 129 (242,
244), 130 (245, 248), 131 (249), 133 (255)
Locally advanced disease, 127 (238), 191 (452), 192 (458),
194 (462)
Metastatic disease, 38 (E18), 87 (99)
Predictive/prognostic factors, 130 (246), 161 (356)

Radiotherapy/adjunct radiotherapy (*cont'd*)

Pulmonary function, 130 (246)
 Quality assurance, 2 (E1), 9 (E4), 127 (237)
 Radiation-induced cancer, 129 (243), 131 (251), 185 (431),
 225 (569)

Rare tumours, 87 (100)

Cystosarcoma phylloides, 216 (535)
 Inflammatory breast cancer, 67 (30), 168 (380)
 Invasive micropapillary carcinoma, 171 (391)
 Medullary breast cancer, 105 (163)

Screening, 216 (538), 236 (610), 243 (635)

Clinical breast examination, 240 (624)
 Cost effectiveness, 241 (628, 629)
 Delayed diagnosis, 194 (463), 239 (623)
 Ductal carcinoma in situ, 176 (411)
 Early detection rate, 53 (1N), 242 (632)
 Frequency of screens, 53 (2N)
 Mammography, 4 (E2), 11 (E5), 22 (E11), 53 (1N), 189 (447),
 225 (570), 239 (621, 622), 240 (625, 626), 242 (631, 633,
 634)
 MRI, 240 (625)
 Public awareness, 42 (E20), 76 (60), 194 (463), 239 (623),
 243 (636), 244 (637)
 Quality assurance, 42 (E20), 241 (629)
 Recommendations, 4 (E2), 42 (E20), 194 (463), 240 (627),
 242 (631, 634), 243 (636), 244 (637)
 Surveillance, 66 (27), 225 (569), 240 (624)
 Ultrasound, 22 (E11)

Sentinel lymph node, 7 (E3), 125 (230), 148 (311), 152 (324),
 153 (326)

After previous excision biopsy, 231 (590)
 Intra-operative pathology assessment, 146 (302), 147 (306),
 148 (308, 310), 150 (316), 151 (320, 322), 152 (323),
 154 (330, 331), 155 (334, 335), 156 (337, 339), 157 (342),
 158 (345, 346), 159 (349, 350)
 Lymphatic flow, 159 (347, 348), 160 (352)
 Metastasis assessment, 54 (4N), 93 (119), 127 (235),
 146 (302, 303, 304), 147 (306), 150 (315, 318), 151 (320,
 322), 152 (325), 153 (329), 154 (330), 155 (335, 336),
 156 (337, 338, 339), 157 (342), 158 (345, 346), 159 (349),
 160 (351)
 Model of predictive value, 127 (235), 146 (304), 149 (312,
 313), 150 (315, 318), 153 (329), 154 (332), 155 (334),
 156 (338), 157 (341), 160 (351)
 Pre-operative technique, 149 (314), 151 (319, 321), 155 (336),
 158 (343), 159 (348)
 Predictive factors for involvement, 54 (4N), 147 (305),
 148 (309), 150 (317), 152 (325), 155 (336), 158 (344),
 159 (347)
 Radioactive tracers, 148 (310), 151 (319)
 Radiopharmaceutical/dye, 153 (327, 328), 155 (333),
 157 (340), 159 (348), 172 (394), 233 (599)
 Ultrasound guided biopsy, 160 (352)
 Validation study, 53 (3N)
 Visualisation, 148 (310), 153 (327), 155 (333, 336), 158 (343),
 159 (347)

Side effects and complications, 24 (E12), 33 (E16), 38 (E18),
 61 (13), 68 (35), 69 (38, 39), 70 (40), 73 (49), 74 (53),
 77 (64), 80 (74), 82 (83), 92 (116), 125 (230), 129 (243),
 130 (245), 132 (254), 134 (260), 136 (267), 137 (271),
 139 (278, 279), 140 (282), 141 (287), 145 (300),
 153 (326), 160 (353), 161 (354, 355, 356), 162 (357,
 359, 360), 163 (361, 362, 363), 164 (364, 365, 366,

367), 165 (368, 369, 370, 371), 166 (372, 373, 374,
 375), 167 (376, 377), 168 (379), 179 (421), 184 (428,
 430), 185 (431), 196 (469), 199 (477, 478), 203 (492),
 205 (499), 209 (513), 210 (515), 212 (524), 216 (536),
 219 (548), 226 (574)

Signal transduction pathways – *see under* Tumour biology

Staging, 53 (3N), 61 (11), 102 (150, 152), 127 (235), 139 (277),
 149 (312, 314), 150 (315), 152 (325), 156 (338),
 158 (343, 345), 160 (351), 170 (389), 223 (562),
 230 (586, 588), 231 (590), 235 (605, 607), 238 (619),
 239 (620)

Supportive treatment, 84 (90), 165 (368, 371), 166 (372),
 168 (379), 188 (445), 191 (452)

Surgery, 83 (87), 161 (355), 162 (358, 360), 208 (509),
 214 (530)

Ambulatory surgery, 133 (257), 218 (542, 544)
 Breast reconstruction, 81 (77), 82 (81), 134 (261), 137 (272),
 138 (273, 274), 139 (279), 141 (286, 287), 142 (289),
 143 (293), 144 (296), 145 (299), 167 (378), 184 (427),
 235 (606)
 Breast Unit, 133 (257)
 Cancer recurrence, 29 (E14), 123 (219), 128 (240), 139 (280),
 190 (451), 207 (506)
 Ductal carcinoma in situ, 135 (262), 148 (309)
 Elderly/geriatric patient care, 136 (265)
 Endoscopic surgery, 140 (283)
 Familial cancer/genetic testing, 136 (268)
 Intra-operative radiotherapy, 130 (248)
 Locally advanced cancer, 138 (276), 194 (462)
 Mastectomy, 54 (5N, 6N), 81 (77), 84 (90), 97 (132),
 103 (153), 126 (232, 233), 128 (240), 134 (261), 136 (268),
 137 (272), 138 (273, 274, 275, 276), 139 (279, 280),
 140 (282), 141 (286), 142 (289), 143 (292, 293), 145 (299),
 167 (378), 194 (464), 206 (500)
 Menstrual cycle, 140 (281)
 MRI guided surgery, 119 (208)
 Neoadjuvant therapy, 68 (33)
 Non-palpable lesions, 146 (301)
 Overview, 119 (208)
 Pain relief, 144 (294)
 Prophylactic surgery, 126 (233), 136 (268), 206 (500)
 Quality assurance, 44 (E21), 122 (218), 142 (288, 290),
 146 (302), 192 (455), 211 (519)
 Radiofrequency ablation, 139 (278)
 Radioguided surgery, 134 (258), 143 (291), 174 (403),
 175 (407)
 Sentinel lymph node dissection – *see* Sentinel lymph node
 Small breast tumours, 176 (408)
 Surgical margins, 133 (256), 135 (262), 142 (290), 146 (301),
 206 (501), 223 (561)
 Surgical techniques, 126 (232), 137 (272), 138 (273, 274,
 275), 139 (279), 140 (283), 141 (286, 287), 142 (289),
 143 (291, 292, 293), 144 (296, 297), 145 (298, 299),
 146 (301), 153 (326), 175 (407), 194 (464)
 Tumour location, 238 (619)
 Ultrasound guided surgery, 134 (259), 146 (301), 174 (400),
 175 (407), 234 (602)

Surgical margins – *see* Surgery

Tamoxifen therapy, 67 (32), 69 (37), 125 (231)

Adjuvant tamoxifen, 66 (28), 67 (30), 73 (51), 166 (374)
 Aromatase inhibitors, 223 (563)

Tamoxifen therapy (*cont'd*)

Early breast cancer, 62 (15)
 Endometrial effects, 67 (31)
 Metastatic/advanced breast cancer, 204 (497)
 Post-menopausal patients, 179 (419)
 Toxicity and side effects, 69 (38), 160 (353), 166 (374),
 179 (419)

Taxanes – see Docetaxel and Paclitaxel**Trastuzumab**, 69 (36), 73 (50), 93 (120)

Early breast cancer, 73 (49), 74 (55), 85 (94)
 First line/single agent, 107 (171), 186 (436), 193 (461)
 Metastatic disease, 217 (540)
 Toxicity and side effects, 68 (35), 162 (357)
 Tumour biology, 113 (189)
 Vinorelbine, 55 (8N)

Triple negative breast cancer, 70 (41), 90 (109), 96 (128),
 98 (135), 99 (141), 105 (160), 108 (172), 110 (180),
 111 (181), 115 (199), 169 (385), 171 (391), 185 (434),
 195 (467), 213 (527), 215 (532), 218 (545), 220 (552),
 221 (554)

Tumour biology, 112 (184), 179 (421)

Angiogenesis, 108 (174), 124 (226)
 Carcinogenesis, 108 (174), 115 (197), 116 (201, 202),
 124 (224, 225), 172 (396), 176 (410)
 Cell cycle, 100 (144), 104 (157), 106 (164, 166)

Drug development, 109 (175), 110 (180), 169 (385),
 177 (414), 178 (416, 417, 418), 183 (425)
 Drug resistance, 183 (425, 426)
 Gene expression, 74 (54), 92 (114, 116), 95 (127), 99 (140),
 107 (170), 108 (174), 109 (175), 110 (179), 112 (185,
 186), 113 (190, 192), 114 (193, 194, 196), 115 (199),
 116 (200, 201), 120 (210), 124 (226), 168 (381), 169 (385),
 172 (396), 178 (416), 187 (439), 188 (443)
 Gene mutations, 93 (118), 108 (172), 109 (177), 111 (183),
 121 (212)
 Growth factors and -receptors, 87 (100), 110 (178)
 Hormone receptors, 74 (54), 109 (176), 110 (180), 111 (182),
 112 (187), 113 (189, 191), 114 (195), 168 (381), 178 (417)
 Metastasis, 107 (168), 115 (199), 124 (225)
 p53, 104 (157)
 Signal transduction pathways, 107 (169), 113 (191)
 TGF-beta, 124 (226)
 Tumour markers, 104 (159), 173 (398), 231 (592)
 Urokinase-type plasminogen activator/inhibitor (uPA/PAI-1),
 112 (186)

Tyrosine kinase inhibitors

Sorafenib, 91 (111)
 Sunitinib, 190 (450)

Young patients, 31 (E15), 77 (64), 101 (149), 105 (160),
 216 (535, 537), 219 (547), 221 (556), 234 (601),
 240 (624)

Zoledronate – see under Bisphosphonates